[{"orgOrder":0,"company":"Research Insight LLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Research Insight LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral","sponsorNew":"Research Insight LLC \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Research Insight LLC \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Mirvetuximab Soravtansine","moa":"||Tubulin | Folate receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Prednisolone Acetate","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Prism Vision Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Prism Vision Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic","sponsorNew":"Prism Vision Group \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Prism Vision Group \/ Inapplicable"},{"orgOrder":0,"company":"Duke University","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"||Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Duke University \/ Ocular Therapeutix","highestDevelopmentStatusID":"9","companyTruncated":"Duke University \/ Ocular Therapeutix"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prednisolone Acetate","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Prednisolone Acetate","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Predonine injection

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          02

                          Lead Product(s) : Cyclosporine,Prednisolone Acetate

                          Therapeutic Area : Ophthalmology

                          Study Phase : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          May 10, 2010

                          Lead Product(s) : Cyclosporine,Prednisolone Acetate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Pred Forte-Generic (prednisolone acetate) is a sterile, topical antiinflammatory agent and is indicated for treating steroid-responsive ocular inflammation.

                          Product Name : Pred Forte-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 12, 2025

                          Lead Product(s) : Prednisolone Acetate,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Pred Forte-Generic (prednisolone acetate) is indicated for the treatment of steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.

                          Product Name : Pred Forte-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 15, 2024

                          Lead Product(s) : Prednisolone Acetate,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Pred Forte-Generic (prednisolone acetate) is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.

                          Product Name : Pred Forte-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 08, 2024

                          Lead Product(s) : Prednisolone Acetate,Inapplicable

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Duke University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Duke University

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          September 24, 2020

                          Lead Product(s) : Dexamethasone,Prednisolone Acetate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Ocular Therapeutix

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Prism Vision Group

                          Country arrow
                          EPSC
                          Not Confirmed

                          Prism Vision Group

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          July 21, 2020

                          Lead Product(s) : Dexamethasone,Prednisolone Acetate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Research Insight LLC

                          Country arrow
                          EPSC
                          Not Confirmed

                          Research Insight LLC

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          February 18, 2020

                          Lead Product(s) : Dexamethasone,Prednisolone Acetate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Carolina Eyecare Physicians, LLC

                          Country arrow
                          EPSC
                          Not Confirmed

                          Carolina Eyecare Physicians, LLC

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 06, 2018

                          Lead Product(s) : Prednisolone Acetate,Gatifloxacin,Bromfenac

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Sponsor : Science in Vision | Imprimis Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Carolina Eyecare Physicians, LLC

                          Country arrow
                          EPSC
                          Not Confirmed

                          Carolina Eyecare Physicians, LLC

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 04, 2015

                          Lead Product(s) : Triamcinolone Acetonide,Moxifloxacin,Vancomycin Hydrochloride,Nepafenac,Moxifloxacin Hydrochloride,Prednisolone Acetate

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase IV

                          Sponsor : Science in Vision

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank